Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMS)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended June 30, 2025
Business Overview: BMS operates as a single segment focused on the discovery, development, and commercialization of innovative medicines for serious diseases, primarily in oncology, hematology, immunology, cardiovascular, and neuroscience.
Key Financial Metrics
| Metric (Dollars in Millions) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Total Revenues | $12,269 | $12,201 | $23,470 | $24,066 |
| Net Earnings Attributable to BMS | $1,310 | $1,680 | $3,766 | $(10,231) |
| Diluted EPS (GAAP) | $0.64 | $0.83 | $1.85 | $(5.05) |
| Operating Cash Flow (YTD) | $5,871 (2025) vs $5,160 (2024) | |||
| Cash and Equivalents | $12,599 (as of June 30, 2025) | |||
| Total Debt (Short + Long Term) | $49,185 (as of June 30, 2025) |
Margins: The filing does not explicitly state gross or operating margin percentages; however, Total Expenses were $10,496 million for Q2 2025 compared to $10,915 million in Q2 2024.
Material Changes vs. Prior Period
- Revenue: Total revenues increased 1% in Q2 2025 and decreased 2% year-to-date compared to 2024. Growth was driven by the Growth Portfolio (up 18% in Q2) and Eliquis, offset by significant declines in the Legacy Portfolio due to generic erosion (Revlimid, Sprycel, Abraxane) and the redesign of the U.S. Medicare Part D program.
- Profitability: GAAP Net Earnings decreased 22% in Q2 2025 ($1,310M vs $1,680M) primarily due to a $1.5 billion one-time Acquired IPRD charge from the BioNTech collaboration and the release of income tax reserves in the prior year. Year-to-date earnings improved significantly from a loss of $10.2 billion in 2024 to a profit of $3.8 billion in 2025, driven by the absence of the $12.1 billion Karuna acquisition charge recorded in 2024.
- Expenses:
- Acquired IPRD: Increased to $1,508 million in Q2 2025 (vs $132M in 2024) due to the BioNTech upfront fee.
- Amortization: Decreased 66% in Q2 2025 ($830M vs $2,416M) as the Revlimid acquired marketed product right was fully amortized in late 2024.
- R&D: Decreased 11% in Q2 2025 ($2,580M vs $2,899M) due to lower impairment charges and cost savings from productivity initiatives.
- Product Performance:
- Growth: Breyanzi (+125%), Camzyos (+87%), and Reblozyl (+34%) showed strong growth. Opdivo increased 7%.
- Legacy: Revlimid (-38%), Sprycel (-72%), and Abraxane (-55%) declined sharply due to generic competition.
Guidance, Outlook, Risks, and Unusual Items
- Strategic Initiatives: BMS expects to realize annual cost savings of approximately $2.0 billion by the end of 2027 through its ongoing strategic productivity initiative. Total charges for the 2023 Restructuring Plan are expected to be approximately $2.5 billion through 2027.
- Unusual Items:
- BioNTech Collaboration: A $1.5 billion upfront payment recorded as Acquired IPRD expense in Q2 2025 for the co-development of BNT327.
- Acquisitions: Completed acquisition of 2seventy bio (May 2025) for $287 million to secure full U.S. rights to Abecma.
- Legal Settlements: Settled the Plavix Hawaii litigation for $350 million in Q2 2025.
- Risks and Contingencies:
- Regulatory/Pricing: Continued pressure from the Inflation Reduction Act (IRA), including price negotiations for Eliquis (effective 2026) and Pomalyst (effective 2027). Potential impact of new executive orders on "Most-Favored Nation" pricing.
- Patent Litigation: Ongoing challenges to Eliquis patents in Europe and pending generic entry for Revlimid and Pomalyst in the U.S. and EU.
- Legal Proceedings: Active litigation regarding Celgene securities, Contingent Value Rights (CVR), and antitrust claims related to Pomalyst and Revlimid.
Investor Verification Checklist
- Acquired IPRD Volatility: Verify the impact of large upfront payments (e.g., BioNTech) on GAAP earnings versus Non-GAAP performance.
- Legacy Portfolio Erosion: Monitor the timeline and volume of generic entry for Revlimid, Pomalyst, and Sprycel, particularly the expiration of volume-limited licenses for Revlimid in Jan 2026.
- Medicare Part D Impact: Assess the long-term revenue impact of the redesigned Medicare Part D program on Eliquis and other high-volume products.
- Restructuring Execution: Track progress toward the $2.0 billion annual cost savings target and the total $2.5 billion charge expectation for the 2023 Restructuring Plan.
- Legal Exposure: Review updates on the Celgene CVR litigation and the outcome of the Plavix Hawaii settlement appeal process.